Kiniksa Pharmaceuticals To Present At Evercore ISI 5Th Annua...| MENAFN.COM

Sunday, 27 November 2022 05:58 GMT

Kiniksa Pharmaceuticals To Present At Evercore ISI 5Th Annual Healthconx Conference


(MENAFN- GlobeNewsWire - Nasdaq)

HAMILTON, Bermuda, Nov. 23, 2022 (GLOBE NEWSWIRE) -- kiniksa pharmaceuticals, ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022 at 10:05 a.m. Eastern Time.

A live webcast of Kiniksa's presentation will be accessible through the Investors & Media section of the company's website at . A replay of the webcast will also be available on Kiniksa's website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's portfolio assets, ARCALYST®, KPL-404, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit  .

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ®
Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437




MENAFN24112022004107003653ID1105227036


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.